2022
When insulin isn’t enough: targeting glucagon in type 1 diabetes
Van Name M, Sherr J. When insulin isn’t enough: targeting glucagon in type 1 diabetes. Nature Medicine 2022, 28: 2007-2008. PMID: 36192555, DOI: 10.1038/s41591-022-02019-3.Commentaries, Editorials and LettersPharmacodynamics, pharmacokinetics, safety, and tolerability of a ready‐to‐use, room temperature, liquid stable glucagon administered via an autoinjector pen to youth with type 1 diabetes
Buckingham B, Sherr J, Prestrelski S, Conoscenti V. Pharmacodynamics, pharmacokinetics, safety, and tolerability of a ready‐to‐use, room temperature, liquid stable glucagon administered via an autoinjector pen to youth with type 1 diabetes. Pediatric Diabetes 2022, 23: 754-762. PMID: 35562186, DOI: 10.1111/pedi.13360.Peer-Reviewed Original ResearchConceptsPlasma glucose concentrationType 1 diabetesAged 2 to <Common adverse eventsAge-appropriate dosesGlucose concentrationGlucagon formulationsManagement of hypoglycemiaPrimary endpointAdverse eventsMedical complicationsPK parametersPharmacodynamicsPharmacokineticsReady-to-useT1DGlucagonHypoglycemiaAge cohortsCohortAutoinjectorPlasmaBaselineAgeYears
2019
Safety and Performance of the Omnipod Hybrid Closed-Loop System in Adults, Adolescents, and Children with Type 1 Diabetes Over 5 Days Under Free-Living Conditions
Sherr J, Buckingham BA, Forlenza G, Galderisi A, Ekhlaspour L, Wadwa RP, Carria L, Hsu L, Berget C, Peyser TA, Lee JB, O'Connor J, Dumais B, Huyett L, Layne JE, Ly TT. Safety and Performance of the Omnipod Hybrid Closed-Loop System in Adults, Adolescents, and Children with Type 1 Diabetes Over 5 Days Under Free-Living Conditions. Diabetes Technology & Therapeutics 2019, 22: 174-184. PMID: 31596130, PMCID: PMC7047109, DOI: 10.1089/dia.2019.0286.Peer-Reviewed Original ResearchConceptsDaily physical activityPhysical activityFree-living conditionsPercentage timeMultiple daily injectionsType 1 diabetesRespective age groupsCohort of participantsHybrid closed-loop systemPrimary endpointDaily injectionsEligible participantsClosed-loop studiesPercentage of timeTherapy phaseInvestigational deviceNights of useAge groupsSensor glucoseType 1Home settingDlSignificant decreaseUsual routineAdults